Analysis

What To Watch As Justices Take On 'Skinny Label' Case

By Ryan Davis · April 27, 2026, 3:12 PM EDT

The U.S. Supreme Court will hear arguments Wednesday on whether to permit a patent suit over a generic heart drug using a so-called skinny label, a case with ramifications for the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Hikma Pharmaceuticals USA Inc., et al., Petitioners v. Amarin Pharma, Inc., et al.

Case Number

24-889

Court

Supreme Court

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

February 19, 2025

Recent Articles By Ryan

April 16, 2026
Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win
April 13, 2026
Hikma Tells Justices Cox Ruling Boosts 'Skinny Label' Case
March 30, 2026
Don't Set Special IP Rules For 'Skinny Labels,' Justices Told
March 23, 2026
Amarin Tells Justices Hikma Drug Patent Appeal Threatens IP
March 19, 2026
Apple Watch Redesign Gets Early OK As Patent Loss Upheld
March 10, 2026
Justices Advised To Keep Law Clear In 'Skinny Label' Case
February 26, 2026
Justices Told 'Skinny Label' Case Puts Generic Drugs At Risk
January 20, 2026
Justices To Clarify What's Fair Game With 'Skinny Labels'
January 16, 2026
Supreme Court Takes On Hikma's 'Skinny Label' Patent Case
December 23, 2025
Justices Urged To Spurn SG's Call To Tackle 'Skinny Labels'